Edition:
United States

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

6.25USD
22 May 2018
Change (% chg)

$-0.09 (-1.42%)
Prev Close
$6.34
Open
$6.32
Day's High
$6.32
Day's Low
$6.24
Volume
4,255
Avg. Vol
58,940
52-wk High
$23.68
52-wk Low
$5.92

Select another date:

Wed, May 9 2018

BRIEF-Protagonist Therapeutics Reports Q1 Net Loss Per Share $0.36

* PROTAGONIST THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Protagonist Therapeutics Discontinues Phase 2B Propel Trial Of PTG-100

* PROTAGONIST THERAPEUTICS DISCONTINUES PHASE 2B PROPEL TRIAL OF PTG-100 FOR THE TREATMENT OF ULCERATIVE COLITIS FOLLOWING INTERIM ANALYSIS

BRIEF-Protagonist Therapeutics Q4 Loss Per Share $0.15

* PROTAGONIST THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

BRIEF-FDA Grants Orphan Drug Designation For Protagonist Therapeutics' PTG-300

* FDA GRANTS ORPHAN DRUG DESIGNATION FOR PROTAGONIST THERAPEUTICS' PTG-300 FOR THE TREATMENT OF BETA-THALASSEMIA Source text for Eikon: Further company coverage:

BRIEF-Protagonist Therapeutics Granted Two New US Patents For Peptide Drug Candidates PTG-100 And PTG-300

* PROTAGONIST THERAPEUTICS GRANTED TWO NEW US PATENTS FOR PEPTIDE DRUG CANDIDATES PTG-100 AND PTG-300 Source text for Eikon: Further company coverage:

BRIEF-Protagonist Therapeutics Appoints Sarah Noonberg To Board

* PROTAGONIST THERAPEUTICS APPOINTS SARAH NOONBERG TO THE BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Protagonist Therapeutics Announces Final Phase 1 Study Results With Novel Hepcidin Mimetic, PTG-300

* PROTAGONIST THERAPEUTICS ANNOUNCES FINAL PHASE 1 STUDY RESULTS WITH NOVEL HEPCIDIN MIMETIC, PTG-300

Select another date: